Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Rhenium-186

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Plus Therapeutics, SpectronRx Partner for REYOBIQ Trial
    Plus Therapeutics, SpectronRx Partner for REYOBIQ Trial

    23 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/23/3279782/0/en/plus-therapeutics-initiates-manufacturing-activities-with-spectronrx-under-a-master-services-agreement-to-support-gmp-pivotal-trial-readiness-for-reyobiq.html

    GLOBENEWSWIRE
    23 Apr 2026
    Share Share
    Plus Therapeutics' Reyobiq Shows Benefit in ReSPECT-LM Trial
    Plus Therapeutics' Reyobiq Shows Benefit in ReSPECT-LM Trial

    14 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/14/3081025/0/en/Plus-Therapeutics-REYOBIQ-Shows-Clinical-Benefit-and-Safety-in-the-ReSPECT-LM-Clinical-Trial-for-Patients-with-Leptomeningeal-Metastases-LM.html

    GLOBENEWSWIRE
    14 May 2025
    Share Share
    Plus Therapeutics Presents New Data on REYOBIQ in ReSPECT-LM Trial
    Plus Therapeutics Presents New Data on REYOBIQ in ReSPECT-LM Trial

    15 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/15/3061606/0/en/Plus-Therapeutics-Presents-New-Data-Highlighting-Clinical-Benefit-and-Safety-of-REYOBIQ-in-the-ReSPECT-LM-Clinical-Trial-for-Patients-with-Leptomeningeal-Metastases.html

    GLOBENEWSWIRE
    15 Apr 2025
    Share Share
    Plus Therapeutics Introduces Reyobiq as FDA-Accepted Name
    Plus Therapeutics Introduces Reyobiq as FDA-Accepted Name

    20 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/20/3046120/0/en/Plus-Therapeutics-Introduces-REYOBIQ-FDA-Accepted-Proprietary-Name-for-Lead-Drug-Candidate.html

    GLOBENEWSWIRE
    20 Mar 2025
    Share Share
    Plus Publishes Ph1 Rhenium-186 Data In Glioblastoma In Nature
    Plus Publishes Ph1 Rhenium-186 Data In Glioblastoma In Nature

    07 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/07/3038883/0/en/Plus-Therapeutics-Announces-Peer-Reviewed-Publication-in-Nature-Communications-Highlighting-Promising-Phase-1-Results-for-Rhenium-186Re-Obisbemeda-in-Glioblastoma.html

    GLOBENEWSWIRE
    07 Mar 2025
    Share Share
    Plus Therapeutics Gets FDA Orphan Drug Nod For Rhenium-186 In Lung Mets
    Plus Therapeutics Gets FDA Orphan Drug Nod For Rhenium-186 In Lung Mets

    06 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/06/3038083/0/en/Plus-Therapeutics-Granted-U-S-FDA-Orphan-Drug-Designation-for-Rhenium-186Re-Obisbemeda-for-the-Treatment-of-Leptomeningeal-Metastases-in-Patients-with-Lung-Cancer.html

    GLOBENEWSWIRE
    06 Mar 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.